Key points are not available for this paper at this time.
surrounding technology for targeting DCs for antigen-specific tolerance and funding from Janssen Biotech Inc. to Uniquest resulting in development and trial of DEN-181. IG, MR, SB, and KC were employees of Janssen when the study took place.
Sonigra et al. (Sun,) studied this question.